LifeMD(US:LFMD) Businesswireยท2025-09-05 17:05Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to alleged securities fraud, with a significant stock price drop following the company's revision of its revenue and EBITDA guidance for 2025 [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA due to temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price fell by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and operations during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in its RexMD segment [3]. - The lawsuit claims that positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period are encouraged to file a lead plaintiff motion by October 27, 2025 [4]. - The law firm Glancy Prongay & Murray LLP is leading the class action and is available for inquiries regarding participation [5][6].